Senti Biosciences Q2 net loss narrows to $12.75 million; revenue turns to $17,000PUBT·21 hours agoSNTI+16.93%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jul 16 at 12:05 PMATPC-0.40%LIMN-6.60%
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga_article·Jul 15 at 12:05 PMCRDF-2.13%SNTI+16.93%
Senti Biosciences to spin off SENTI-202 assets to Celadon-backed NewCo for CVR worth up to $60 millionPUBT·Jul 15 at 06:31 AMSNTI+16.93%
Senti Biosciences Faces Severe Refinancing and Liquidity Risks from Costly Note StructureTip Ranks·May 16 at 01:00 AMSNTI+16.93%
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase | SNTI Stock NewsStockTitan·May 13 at 11:45 PMSNTI+16.93%
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program | SNTI Stock NewsStockTitan·May 13 at 11:40 PMSNTI+16.93%
Senti Biosciences Holdings shares are trading lower after the company announced it entered into a $40 million convertible note financing agreement with Celadon Affiliate.benzinga_article·May 4 at 08:03 AMSNTI+16.93%SBIO+0.54%
Senti Biosciences Secures Convertible Note Financing with CeladonTip Ranks·May 1 at 03:46 PMSNTI+16.93%
